Delivering a Next Generation Platform for Antibody Drug Discovery

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple companies and continues making the AlivaMab Mouse available via non-exclusive licenses.

Year Invested: 2009
Location: San Francisco, Calif.

Recent News

September 14, 2017
Ablexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics

February 14, 2017
Ablexis Announces Perpetual License Agreement for AlivaMab Mouse with Janssen

July 20, 2016
Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma

Read More News

Associated Team Members

Cary Pfeffer, M.D.